IE
TRVI icon

Israel Englander’s Trevi Therapeutics TRVI Stock Holding History

Israel Englander’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-570,971
Closed -$6.81M – 6414
2026
Q1 		$6.81M Buy
570,971
+745
+0.1% +$8.34K ﹤0.01% 2592
2025
Q4 		$7.14M Sell
570,226
-157,370
-22% -$1.82M ﹤0.01% 2637
2025
Q3 		$6.66M Buy
727,596
+570,352
+363% +$4.28M ﹤0.01% 2831
2025
Q2 		$860K Sell
157,244
-666,005
-81% -$4.14M ﹤0.01% 4522
2025
Q1 		$5.18M Buy
823,249
+642,830
+356% +$3.07M ﹤0.01% 2826
2024
Q4 		$743K Buy
180,419
+159,798
+775% +$512K ﹤0.01% 4432
2024
Q3 		$68.9K Buy
+20,621
New +$61.3K ﹤0.01% 5651
2024
Q1 		– Sell
-119,793
Closed -$161K – 6663
2023
Q4 		$161K Buy
+119,793
New +$181K ﹤0.01% 5235
2023
Q2 		– Sell
-59,628
Closed -$110K – 6694
2023
Q1 		$110K Sell
59,628
-97,996
-62% -$222K ﹤0.01% 5392
2022
Q4 		$304K Buy
157,624
+117,663
+294% +$232K ﹤0.01% 5097
2022
Q3 		$62K Sell
39,961
-26,222
-40% -$86K ﹤0.01% 6113
2022
Q2 		$186K Sell
66,183
-18,697
-22% -$45.9K ﹤0.01% 5673
2022
Q1 		$187K Sell
84,880
-36,612
-30% -$37.9K ﹤0.01% 5851
2021
Q4 		$95K Buy
+121,492
New +$128K ﹤0.01% 6277
2019
Q3 		– Sell
-12,300
Closed -$92K – 4566
2019
Q2 		$92K Buy
+12,300
New +$106K ﹤0.01% 3901

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Israel Englander's TRVI Position: Q2 2026 in Review

Israel Englander sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 570,971 shares — an estimated $6.81M sold.

Israel Englander first reported a position in TRVI in Q2 2019 and held it in 15 quarters. The position peaked at $7.14M in Q4 2025. 216 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Israel Englander reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 570,971 Trevi Therapeutics shares in Q2 2026, an estimated $6.81M.
  • Israel Englander first reported a position in Trevi Therapeutics in Q2 2019 and held it in 15 quarters.
  • Israel Englander's Trevi Therapeutics position peaked at $7.14M in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.